Processing

Please wait...

Settings

Settings

Goto Application

1. WO2012065106 - COMPOUNDS AND RELATED METHODS FOR MANIPULATING PARP-1-DEPENDENT CELL DEATH

Publication Number WO/2012/065106
Publication Date 18.05.2012
International Application No. PCT/US2011/060439
International Filing Date 11.11.2011
IPC
A61K 38/17 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
C07K 14/435 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
C12N 15/12 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
A61P 25/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 25/28 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 3/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
A61P 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
A61P 13/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
12of the kidneys
A61P 19/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
02for joint disorders, e.g. arthritis, arthrosis
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 25/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
14for treating abnormal movements, e.g. chorea, dyskinesia
Applicants
  • DAWSON, Ted M. [US]/[US]
  • DAWSON, Valina L. [US]/[US]
  • WANG, Yingfei [US]/[US]
Inventors
  • DAWSON, Ted M.
  • DAWSON, Valina L.
  • WANG, Yingfei
Agents
  • CROWSON, Celine Jimenez
Priority Data
61/412,41911.11.2010US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMPOUNDS AND RELATED METHODS FOR MANIPULATING PARP-1-DEPENDENT CELL DEATH
(FR) COMPOSÉS ET PROCÉDÉS ASSOCIÉS POUR MANIPULATION DE LA MORT CELLULAIRE DÉPENDANTE DE PARP-1
Abstract
(EN)
Apoptosis inducing factor ("AIF") contains a PAR-binding motif ("PBM") that binds to Poly(ADP-ribose) ("PAR"). Binding of PAR to AIF via the PBM is required for AIF release from the mitochondria to occur, and that this PAR-related release is a key step in the programmed cell death process known as parthanatos, both in vitro and in vivo. Preventing or disrupting this release can inhibit parthanatos and thus be the basis for treatments for patients suffering from diseases or medical conditions during which parthanatos commonly occurs, including Parkinson's disease or diabetes, or patients who have had and are recovering from heart attack, stroke and other ischemia reperfusion-related injuries. Alternatively, agents could be identified that enhance the release of AIF, thereby promoting parthanatos and serving as potential anti-tumor chemotherapeutic agents.
(FR)
Selon l'invention, le facteur induisant l'apoptose (« AIF ») contient un motif de liaison à PAR (« PBM ») qui se lie au poly(ADP-ribose) (« PAR »). La liaison de PAR à AIF par l'intermédiaire du PBM est nécessaire pour la libération d'AIF de la mitochondrie, et cette libération associée à PAR est une étape-clé dans le processus de mort cellulaire programmée, connue en tant que parthanatose, à la fois in vitro et in vivo. La prévention ou la perturbation de cette libération peut inhiber la parthanatose et par conséquent être la base de traitements pour des patients souffrant de maladies ou d'états médicaux au cours desquels la parthanatose a communément lieu, comprenant la maladie de Parkinson ou le diabète, ou des patients qui ont eu une crise cardiaque, un accident vasculaire cérébral et d'autres lésions associées à une ischémie de reperfusion, et qui sont en convalescence. En variante, des agents ont pu être identifiés qui augmentent la libération d'AIF, promouvant ainsi la parthanatose et servant en tant qu'agents chimiothérapiques anti-tumoraux potentiels.
Latest bibliographic data on file with the International Bureau